Brief: Oncolytics says ovarian cancer drug shows benefit in mid-stage study
March 21 (Reuters) - Oncolytics Biotech
* Update for randomized phase ii clinical trial reolysin in
combination with paclitaxel in patients with ovarian cancer
* Performed an intent-to-treat analysis of tumour response,
which showed statistically significantly higher full response
rates
Source text for Eikon: ID:nCNWsCbgka
Further company coverage: ONC.TO
(Bengaluru Newsroom: +1-646-223-8780)
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Announces Clinical Supply Agreement To Evaluate Pelareorep In Combination With Loqtorzi In Squamous Cell Anal Carcinoma
Brief: Oncolytics Says Pelareorep Shows Durable Survival Benefit in Anal Cancer
Brief: Oncolytics Biotech Expects Final Cohort 4 Results Of Goblet Study In Q4 2026
Brief: Oncolytics Biotech® Secures Patent Protection To Late 2040S And Provides Intellectual Property Portfolio Update
Brief: Oncolytics Biotech® Aligns With FDA On Registrational Path For Second-Line Ras-Mutant Mss Colorectal Cancer